Quote this publication Share Print

EYLEA (aflibercept), anti-VEGF

OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Jan 25 2016

Reason for request

Extension of inclusion

Minor improvement in the management of visual impairment secondary to branch retinal vein occlusion.

 

  • EYLEA now has Marketing Authorisation in the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO).
  • Its efficacy has been demonstrated versus laser photocoagulation but it has not been compared with LUCENTIS or OZURDEX.
  • Like LUCENTIS, it is a first-line treatment that provides minor clinical added value in the management of visual impairment secondary to BRVO.

 


Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Therapeutic use

-

Contact Us

Évaluation des médicaments
All our publications